

Dr. B. Lal Clinical Laboratory Pvt Ltd

6-E, Malviya Industrial Area, Malviya Nagar, Jaipur-302017

Website: www.blallab.com, Customer care: Ph.+91-91661 25555

Mail Id: customercare@blallab.com CIN: U33125RJ1994PTC009129

TEST REPORT

Lab Serial No. :962106000031

Patient Name: Mr. ANIL KUMAR

Referred by : Dr. SELF :27 YRS / M Age/Gender

Source BY

SIN No., Date

: **96004328** 03-Jun-21 02:12 PM

Sample collection date : 03-Jun-2021 02:13PM : 03-Jun-2021 02:59PM Report Date

: 03-Jun-2021 03:00PM Report printed on

SEROLOGY

Test Name Observation Unit Biological Ref. interval

ANTI-SARS-Cov-2 IgG SPIKE ANTIBODY

ANTI-SARS-Cov-2 IgG SPIKE ANTIBODY

234.6

Au/mL

Guide Value:-

- < 50 Negative Indicates Absence of SARS-Cov-2 Spike Antibodies
- > 50 Positive Indicates presence of SARS-Cov-2 Spike Antibodies

Remarks:

- 1. The SARS-CoV-2 IgG II Quant assay is a chemiluminescent microparticle immunoassay (CMIA) used for the qualitative and quantitative determination of IgG antibodies.
- 2. The assay is also to be used as an aid in evaluating immune status of individuals with quantitative measurement of IgG antibodies against the spike receptor-binding domain (RBD) of SARS-CoV-2. Results.

Limitations:

- 1. Results should be used in conjunction with other data; e.g., symptoms, results of other tests, and clinical impressions.
- 2. Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus. Follow-up testing with a molecular diagnostic should be considered to rule out infection in these individuals.
- 3. Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection
- 4. Immunocompromised patients who have COVID-19 may have a delayed antibody response and produce levels of antibody which may not be detected as positive by the assay. • The persistence of a SARS-CoV-2 immune response has not been fully established. Negative results may be observed due to a decline in antibody titer over time.
- 5. Potential interference has not been evaluated for substances other than those described in the SPECIFIC PERFORMANCE

Dr. B. Lal Gupta MD Microbiology Medical Director

Dr. Ruhi Munjal DCP Pathology

Dr. Neha Shivran M.D Biochemistry





Dr. B. Lal Clinical Laboratory Pvt Ltd

6-E, Malviya Industrial Area, Malviya Nagar, Jaipur-302017 Website: www.blallab.com, Customer care: Ph.+91-91661 25555

website. www.btattab.com, Customer care. Pn.+

Mail Id: customercare@blallab.com CIN: U33125RJ1994PTC009129

TEST REPORT

Lab Serial No. :962106000031

Patient Name : Mr. ANIL KUMAR

Referred by : **Dr. SELF**Age/Gender : 27 YRS / M

Source BY

SIN No., Date :96004328 03-Jun-21 02:12 PM

Sample collection date : 03-Jun-2021 02:13PM

Report Date : 03-Jun-2021 02:59PM

Report printed on :03-Jun-2021 03:00PM

SEROLOGY

Test Name Observation Unit Biological Ref. interval

CHARACTERISTICS section of this package insert.

- 6. Specimens from patients who have received preparations of mouse monoclonal antibodies for diagnosis or therapy may contain human anti-mouse antibodies (HAMA). Such specimens may show either falsely elevated or depressed values when tested with assay kits such as SARS-CoV-2 IgG II Quant that employ mouse monoclonal antibodies.40, 41
- 7. Heterophilic antibodies in human serum can react with reagent immunoglobulins, interfering with in vitro immunoassays. Patients routinely exposed to animals or to animal serum products can be prone to this interference, and anomalous values may be observed.42
- 8. Rheumatoid factor (RF) in human serum can react with reagent immunoglobulins, interfering with in vitro immunoassays.

Reference: Kit insert Anti-SARS-CoV-2 IgG II Quant from Architect.

*** End of report ***

Dr. B. Lal Gupta MD Microbiology Medical Director

Dr. Ruhi Munjal DCP Pathology Dr. Neha Shivran M.D Biochemistry

